ATF4 and neoplasm: Overall, the lower toxicity profile following transient ATF4 deletion in mice, coupled with the demonstrated pro-tumourigenic role of ATF4 in a tumour-intrinsic manner, further supports the notion that a clinically useful therapeutic window may exist for ATF4 inhibition as an attractive antitumour modality.